Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness (Q24674358)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness |
scientific article |
Statements
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness (English)
0 references
September 2007
0 references
91
0 references
9
0 references
1244-6
0 references
1 reference